

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5260429

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
EVOTEC (UK) LTD.	10/13/2014
RECEIVING PARTY DATA	
Name:	CHDI FOUNDATION, INC.
Street Address:	C/O CHDI MANAGEMENT, INC.
Internal Address:	350 SEVENTH AVENUE, SUITE 200
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10001
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15948821
CORRESPONDENCE DATA	
Fax Number:	(650)815-2601
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508152600
Email:	abaker@sheppardmullin.com, svipdocketing@sheppardmullin.com
Correspondent Name:	SHEPPARD MULLIN RICHTER & HAMPTON LLP
Address Line 1:	379 LYTTON AVENUE
Address Line 2:	JOY NEMIROW
Address Line 4:	PALO ALTO, CALIFORNIA 94301
ATTORNEY DOCKET NUMBER:	49DX-226843-US2
NAME OF SUBMITTER:	JOY NEMIROW
SIGNATURE:	/Joy Nemirow/
DATE SIGNED:	11/30/2018
Total Attachments: 4	
source=226843-US2_EvotectoCHDIAssignment#page1.tif	
source=226843-US2_EvotectoCHDIAssignment#page2.tif	
source=226843-US2_EvotectoCHDIAssignment#page3.tif	
source=226843-US2_EvotectoCHDIAssignment#page4.tif	

PATENT ASSIGNMENT

WHEREAS Evotec (UK) Ltd., of 114 Milton Park, Abingdon Oxfordshire OX14 4SA, United Kingdom, (hereinafter referred to as "ASSIGNOR") is the owner of the following patent applications, and the invention(s) set forth therein, as shown by the records of the United States Patent and Trademark Office:

Patent Application No.	Filing Date	Title
PCT/US14/56887	September 23, 2014	Kynurenine-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof

WHEREAS CHDI Foundation, Inc., of 350 Seventh Avenue, Suite 601, New York, New York 10001 (hereinafter referred to as "ASSIGNEE") is desirous of acquiring the full right, title and interest in and to said inventions and in and to said patent applications for the United States, its territories and possessions, and all foreign countries:

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by ASSIGNOR, ASSIGNOR has sold, assigned, transferred and set over, and by these presents hereby sells, assigns, transfers and sets over to ASSIGNEE the entire and exclusive right, title and interest in and to said inventions and in and to said patent applications listed above, including any and all divisional, continuation, continuation-in-part, reissues or extensions thereof, for the United States, its territories and possessions, and all foreign countries, to be held and enjoyed by ASSIGNEE for its own use as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment not been made; the Commissioner of Patents and Trademarks of the United States of America is hereby authorized to transfer the portion of the title indicated to said application to said ASSIGNEE in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the ASSIGNOR, but also that such assigned rights are not encumbered by any grant, license, or other right theretofore given; ASSIGNOR hereby undertakes to execute and deliver to ASSIGNEE upon request all lawful documents which may be requested by ASSIGNEE, and to furnish ASSIGNEE with all facts relating to said invention as may be requested.

Date: 13 OCT 2014

Evotec (UK) Ltd.

By: P. Elan

Name: DR DAVID HALLETT

Title: EV CHEMISTRY

Accepted by:

CHDI Foundation

By: _____

Date: _____

Name: _____

Title: _____

CHDI Management, Inc. as authorized agent of CHDI Foundation, Inc. by Robt. Zimmermanstein, President - CHDI Management

PATENT ASSIGNMENT

WHEREAS Evotec (UK) Ltd., of 114 Milton Park, Abingdon Oxfordshire OX14 4SA, United Kingdom, (hereinafter referred to as "ASSIGNOR") is the owner of the following patent applications, and the invention(s) set forth therein, as shown by the records of the United States Patent and Trademark Office:

Patent Application No.	Filing Date	Title
PCT/US14/56887	September 23, 2014	Kynurenine-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof

WHEREAS CHDI Foundation, Inc., of 350 Seventh Avenue, Suite 601, New York, New York 10001 (hereinafter referred to as "ASSIGNEE") is desirous of acquiring the full right, title and interest in and to said inventions and in and to said patent applications for the United States, its territories and possessions, and all foreign countries:

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by ASSIGNOR, ASSIGNOR has sold, assigned, transferred and set over, and by these presents hereby sells, assigns, transfers and sets over to ASSIGNEE the entire and exclusive right, title and interest in and to said inventions and in and to said patent applications listed above, including any and all divisional, continuation, continuation-in-part, reissues or extensions thereof, for the United States, its territories and possessions, and all foreign countries, to be held and enjoyed by ASSIGNEE for its own use as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment not been made; the Commissioner of Patents and Trademarks of the United States of America is hereby authorized to transfer the portion of the title indicated to said application to said ASSIGNEE in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the ASSIGNOR, but also that such assigned rights are not encumbered by any grant, license, or other right theretofore given; ASSIGNOR hereby undertakes to execute and deliver to ASSIGNEE upon request all lawful documents which may be requested by ASSIGNEE, and to furnish ASSIGNEE with all facts relating to said invention as may be requested.

Date: _____

Exotec (UK) Ltd.

By: _____

Name: _____

Title: _____

Accepted by:

CHDI Foundation

By: *Roni Blumenthal*

Date: *10/15/14*

Name: *Roni Blumenthal*

Title: *President*

CHDI Management, Inc. as authorized agent of CHDI Foundation, Inc. by Roni Blumenthal, President - CHDI Management